PRPH - ProPhase Labs Corp Long-Term Liabilities to Capital

ProPhase Labs, Inc. (PRPH) relies on a network of diagnostic centers and the sale of dietary supplements. The long-term financial leverage ratio visualizes the current balance of debt and equity, where 0.14 expresses the latest level of the metric. The holding company utilizes resources from PCR tests to develop genomics and oncology, although a decline in demand for testing has temporarily increased the company's unit costs.

When constructing a long-term portfolio, fundamental screening requires strict control over debt load. This ratio compares liabilities with maturities exceeding one year to total equity, determining the degree of financial leverage. For ProPhase Labs, Inc. (PRPH), which is developing diagnostics and nutraceuticals, moderate leverage is critical when scaling pharmacy sales. By analyzing the long-term debt-to-equity chart, an investor assesses the stability of the financing structure, which allows for the determination of the risk associated with the business's dependence on external borrowings.